Bioasis Technologies (BIOAF) 1.1100 $BIOAF biOasis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioasis Technologies (BIOAF) 1.1100 $BIOAF

biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC
Marketwired - Thu Apr 21, 5:28PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company" announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC ("Astellas" . The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the internalization and assessment of the biOasis Transcend technology.
BTI.VN: 1.480 (+0.050)

biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain
Marketwired - Thu Mar 17, 10:37PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company" on Saturday, March 19, 2016 at 11:45am, will present the data from the biOasis sponsored Brains for Brain ("B4B" lysosomal storage disease ("LSD" knockout mouse study performed by Dr. Maurizio Scarpa and Dr. Rosella Tomanin at Dr. Scarpa's laboratories in Padova, Italy. Dr. Scarpa is a world leading clinical expert in lysosomal storage diseases.
BTI.VN: 1.480 (+0.050)

biOasis Technologies Inc. - Product Pipeline Review Market Size, Share & Forecast to 2015: Radiant Insights, Inc
M2 - Fri Jan 22, 3:06AM CST
Summary

Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 35.15 (-0.04), SPPI: 5.93 (+0.02), BMY: 58.79 (+0.11), STML: 7.33 (+0.01), ONTY: 1.21 (+0.02), NKTR: 17.72 (+0.06), MEIP: 1.94 (-0.09), ATNM: 1.65 (-0.04), ABBV: 66.77 (-0.06), EXEL: 10.97 (+0.35), NVS: 81.54 (-0.40)

Kalytera Therapeutics elects Ronald P. Erickson to board
M2 - Fri Dec 04, 6:05AM CST
Pharmaceutical company Kalytera Therapeutics revealed on Thursday the addition of Ronald P. Erickson to its board of directors.

Kalytera Therapeutics Appoints Ronald P. Erickson to Board of Directors
Marketwired - Thu Dec 03, 6:08PM CST
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid ("CBD" and synthetic CBD medicines intended to address the unmet needs of large patient populations, today announced it has appointed Ronald P. Erickson to its Board of Directors.

biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
Marketwired - Sun Nov 29, 2:58PM CST
biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) ("biOasis or the "Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier ("BBB" , announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company's Transcend BBB delivery vector.
BTI.VN: 1.480 (+0.050)

biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies -- Inclusive of Trastuzumab -- to Treat Her2/neu Brain Metastases
Marketwire Canada - Tue Nov 10, 4:00PM CST
BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the full and final issuance of a US patent covering the delivery by Transcend of cancer therapeutics to the brain to treat an aggressive form of brain cancer -- Her2+/nue brain metastases.
BTI.VN: 1.480 (+0.050)

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review Report H2 2015
M2 - Mon Nov 09, 9:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/zxt8qr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2015" report to their offering. The report Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2015', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and special features on late-stage and discontinued projects. Companies Mentioned - Alexion Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Laboratorios Del Dr. Esteve S.A. - RegenxBio Inc. - Sangamo BioSciences, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/zx...saccharido
FATE: 2.92 (+0.10), SHPG: 197.66 (-0.94), SGMO: 4.42 (+0.01), ALXN: 132.43 (-0.63)

Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Review, H2 2015 - 10 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2932sl/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - ArmaGen Technologies, Inc. - Athersys, Inc. - biOasis Technologies Inc. - Fate Therapeutics, Inc. - OPKO Health, Inc. - PTC Therapeutics, Inc. - RegenxBio Inc. - Sangamo BioSciences, Inc. Drug Profiles - AGT-181 - ataluren - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - FT-1050 - laronidase chaperone - MultiStem - Oligonucleotide for Mucopolysaccharidosis I - Recombinant Enzyme to Replace Alpha-L-Iduronidase for Hurler Syndrome - Recombinant Enzyme to Target LRP1 for Mucopolysaccharidosis I - RGX-111 - SB-318 - Stem Cell Therapy for Type1 Mucopolysaccharidosis For more information visit http://www.researchandmarkets.com/research/29...saccharido
FATE: 2.92 (+0.10), OPK: 9.80 (-0.06), SGMO: 4.42 (+0.01), PTCT: 8.14 (+0.03), ATHX: 2.02 (+0.07), FOLD: 7.01 (+0.14)

biOasis Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 28, 4:16PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQB: BIOAF) (the "Company" wishes to announce, that as part of its going forward strategy, its current listing on the OTCQX will be changing to a listing on the OTCQB. The Company's trading symbol will remain BIOAF.
BTI.VN: 1.480 (+0.050)

TSX Venture Exchange Daily Bulletins
CNW Group - Thu Aug 27, 3:31PM CDT
TSX VENTURE COMPANIES

Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 313.38 (-0.44), ATNM: 1.65 (-0.04), AMGN: 174.75 (+0.44), CELGZ: 1.11 (-0.12)

biOasis to extend share purchase warrants exercise date
M2 - Mon Aug 17, 7:35AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE: BTI) said on Friday that it plans to extend the exercise date of its 1,599,477 warrants currently exercisable until 29 August 2015 to 31 December 2015.
BTI.VN: 1.480 (+0.050)

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 1.65 (-0.04), ADRO: 15.20 (+0.07), AMBX: (), AZN: 33.66 (+0.09), AMGN: 174.75 (+0.44), AMPE: 0.90 (unch), ABBV: 66.77 (-0.06), BMY: 58.79 (+0.11), AAAP: 32.35 (+0.34)

biOasis Announces Extension of Share Purchase Warrants
Marketwired - Fri Aug 14, 12:00PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" wishes to announce that it will make an application to extend the exercise date of its 1,599,477 warrants currently exercisable until August 29, 2015 (the "Warrants" . The Warrants were issued with an original term of 12 months in connection with the closing of a private placement financing as announced by the Company on August 29, 2015. A total of 30,530 of the Warrants are held by an insider of the Company who participated in the private placement. The extension of the expiry of the Warrants is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 ("MI 61-101" by virtue of the exemptions contain in section 5.5(a) and 5.7(1) (a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company issued to an insider does not exceed 25% of its market capitalization.
BTI.VN: 1.480 (+0.050)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 266

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 18

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Meat Partners with Hard Rock Cafe for Burger Launch

Updated Category News Views 432

Beyond Meat and Hard Rock Cafe Collaboration Beyond Meat, Inc. (NASDAQ: BYND), an innovator in plant-based proteins, is excited to announce a partnership with Hard Rock Cafe, introducing the newest Beyond Burger across all its North American locations. This initiative allows diners to swap any beef burger from Hard Rock's core and kids' menus for the delicious and...

Continue Reading
ATEC Water Systems Welcomes Industry Leader Steve Green

Updated Category News Views 299

ATEC Water Systems welcomed Steve Green as their new Chief Commercial Officer back in 2024, shaking things up under the Cadiz, Inc. (NASDAQ: CDZI) umbrella. Traders watched closely; this wasn't just a run-of-the-mill hire but rather a strategic move aimed at revitalizing the company's trajectory in a crowded market. With Steve's extensive background in the water industry,...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 249

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading
Ascot Resources Explores Alternative TSXV Listing Options

Updated Category News Views 165

Ascot Resources Faces Delisting from TSX Ascot Resources Ltd., a Canadian mining company headquartered in Vancouver, is going through significant changes regarding its stock listings. Recently, the Continued Listing Committee of the Toronto Stock Exchange (TSX) informed Ascot that its common shares are set to be delisted at the market's close on a specified date. This...

Continue Reading
Albany International Corporation Faces Legal Scrutiny Amid Stockholder Concerns

Updated Category News Views 194

Introduction to the Investigation Albany International Corporation is currently experiencing legal scrutiny as concerns arise among stockholders regarding the company's financial performance. Recently, the law firm Bragar Eagel & Squire, P.C. has stepped in, urging investors who may have suffered losses in Albanian stocks to reach out for assistance. The firm seeks to...

Continue Reading